$2.62
0.77% today
Nasdaq, Sep 03, 06:49 pm CET
ISIN
US6294441000
Symbol
NRXP

NRX Pharmaceuticals Inc Stock price

$2.60
-0.12 4.41% 1M
+0.57 28.08% 6M
+0.40 18.18% YTD
+0.73 39.04% 1Y
-4.15 61.49% 3Y
-104.20 97.57% 5Y
-93.40 97.29% 10Y
-93.40 97.29% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.28 12.07%
ISIN
US6294441000
Symbol
NRXP
Industry

Key metrics

Basic
Market capitalization
$61.8m
Enterprise Value
$69.1m
Net debt
$7.3m
Cash
$2.9m
Shares outstanding
19.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 1.9
EV/Sales
- | 2.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-636.1%
Return on Equity
108.2%
ROCE
39.7%
ROIC
-
Debt/Equity
-0.3
Financials (TTM | estimate)
Revenue
$0.0 | $33.2m
EBITDA
$-14.1m | -
EBIT
$-14.1m | $-3.3m
Net Income
$-33.8m | $-3.6m
Free Cash Flow
$-11.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
39.3% | -
EBIT
39.2% | 83.1%
Net Income
-36.1% | 85.8%
Free Cash Flow
14.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -10.8%
Free Cash Flow
-
More
EPS
$-1.9
FCF per Share
$-0.6
Short interest
3.0%
Employees
-
Rev per Employee
-
Show more

Is NRX Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

NRX Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a NRX Pharmaceuticals Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a NRX Pharmaceuticals Inc forecast:

Buy
90%
Hold
10%

Financial data from NRX Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
17% 17%
-
- Research and Development Expense 3.44 3.44
67% 67%
-
-14 -14
39% 39%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -14 -14
39% 39%
-
Net Profit -34 -34
36% 36%
-

In millions USD.

Don't miss a Thing! We will send you all news about NRX Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NRX Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
about 5 hours ago
WILMINGTON, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that Jonathan Javitt, M.D.
Neutral
GlobeNewsWire
one day ago
SOUTHAMPTON, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, presented two keynote talks to a gathering of leading family offices and family members sponsored by the Global Passion Project and the Rockefeller Global Family Office on August 28-30, 2025 in Southampton, NY. The Company's CEO, Prof. Jonathan Javitt, MD, M...
Neutral
GlobeNewsWire
one day ago
SOUTHAMPTON, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, presented two keynote talks to a gathering of leading family offices and family members sponsored by the Global Passion Project and Rockefeller Capital on August 28-30, 2025 in Southampton, NY. The Company's CEO, Prof. Jonathan Javitt, MD, MPH spoke alongsid...
More NRX Pharmaceuticals Inc News

Company Profile

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Head office United States
CEO Jonathan Javitt
Founded 2017
Website www.nrxpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today